Regulators expand review time for Novartis’ MS drug
Regulatory action is now expected in September 2020
Read More
Tag: Arzerra
Genmab/Novatis’ Arzerra fails to hit NHL targets
Adding Arzerra to treatment with Treanda has failed to significantly extend progression-free survival in patients with indolent B cell non-Hodgkin’s lymphoma.
Read More
US expands use of Novartis/Genmab’s Arzerra
US regulators have expanded the approved uses of Novartis/Genmab’s Arzerra so that the biologic can now be used alongside fludarabine and cyclophosphamide for the treatment of patients with relapsed chronic lymphocytic leukaemia.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
